Extending detection beyond melanoma Keratinocyte cancers – including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) – are the most common skin cancers. Nevisense supports detection of these cancers using the same EIS and AI technology proven in melanoma diagnostics.
Helps prioritize lesions for biopsy and treatment.
One platform, several applications
Nevisense lets clinicians assess both melanoma and non-melanoma lesions with a single system, increasing its value across dermatology practices.
Non-invasive lesion evaluation
Nevisense provides objective support when evaluating suspicious lesions, helping clinicians make more informed biopsy decisions.
Early intervention support
Early identification of BCC and SCC enables timely treatment, improving patient outcomes.
Benefits for clinical teams
Nevisense helps: • Obtain objective information when evaluating suspicious lesions • Increase diagnostic confidence in uncertain cases • Make more informed decisions about whether to biopsy
• Provide patients with a non-invasive assessment at the point of care
(Ref. 1 - 2)
BOOK A DEMO
Discover how Nevisense can support your clinical workflow
Book a personalized demonstration to learn how Nevisense can complement your current diagnostic process and provide objective support for clinical decision-making.
References: 1. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multi-center, prospective and blinded clinical trial on efficacy and safety, Malvehy et al BJD, 2014 DOI: 10.1111/bjd.13121. 2. 2020 Sarac, Garbe, Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer, Acta Derm Veneorol DOI: 10.2340/00015555-3689
Supports detection of both BCC and SCC.
